BioXcel stock: buy or sell?

BTAI stock price: $45.85 6.45% At close on May 14th, 2020

Updated on:
May 14th, 2020

0

BioXcel Therapeutics shares rocketed 6.45% today and marked a new all time high at $46.12. On May/12 BTAI plunged a bloodcurdling -5.73%.

Should I buy BioXcel stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

These 2 buy setups match with BioXcel stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is BioXcel Therapeutics stock a buy?

Financial institutions and banks post stock ratings everyday. Unfortunately, we couldn't detect any rating for BTAI stock for the last 30 days.

BioXcel stock analysis

Daily outlook

BioXcel set new all time highs back again today, setting highs to $46.12. Shares ended at $45.85 and rocketed 6.45%.

BioXcel Therapeutics shares rocketed 6.45% today and set a new all time high at $46.12. Since February when SMA100d and SMA200d crossed up, BTAI price gained $6.26 per share (15.81%). From a daily perspective, BTAI is in a short term uptrend after plotting its last bottom ($33.20, on May 1st) higher than the previous bottom, and its last top ($42.50, on May 5th) also over the previous top. Now trading in between its last bottom and last top BTAI might consolidate in a plain range, waiting to break out over $42.50 or down under $33.20. Since last December when BTAI stock price broke up the SMA200d line, it gained $37.54 (451.74%).

BTAI stock chart (daily)

Weekly outlook

BioXcel shares boosted 13.46% this week and set a new all time high at $46.12. Late March BTAI plunged a frightening -38.65% in just one week. For 5 weeks in a row, price soared and marked a profit of 128.43%.

BTAI shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom by mid March, BTAI climbed unceasignly breaking out to new all time highs. By mid February, SMA20w and SMA40w crossed up triggering a rise of 129.25%. Since late December 2019 when BTAI stock price broke up the SMA40w line, it gained $37.54 (451.74%).

BTAI stock chart (weekly)

BioXcel stock price history

BioXcel stock went public on March 8th, 2018 with a price of $11.021. Since then, BTAI stock grew a 316.10%, with a yearly average of 158.10%. If you had invested $1,000 in BioXcel stock in 2018, it would worth $3,161.00 today.

1: Adjusted price after possible price splits or reverse-splits.

BioXcel stock historical price chart

BTAI stock reached all-time highs today with a price of $46.12.

BioXcel stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not found any price prediction for BioXcel stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, BioXcel Therapeutics reported its latest financial data, posting an amazing gain for the Earnings per Share (EPS). Analyst were expecting $-0.34 per share, but BioXcel posted $-0.47.
BTAI earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/a-0.07n/a
2017-Q3-n/a-0.06n/a
2017-Q4-n/a-0.17n/a
2018-Q12018-05-14-0.21-0.37n/a
2018-Q22018-08-08-0.35-0.19n/a
2018-Q32018-11-09-0.26-0.31n/a
2018-Q42019-03-07-0.34-0.47n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In , BioXcel Therapeutics annual turnover to million dollars from marked in . , its profit margin (compared to sales) to , that is million.

BTAI annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter income marked $-7.08 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, BioXcel Therapeutics sales marked a neutral move and remained stable a nan%. Looking back to recent quarterly results, BioXcel Therapeutics posted 7 negative quarters in a row.
BTAI quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

BioXcel ownership

When you are planning to buy a stock, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For BioXcel, 48.51% of all outstanding shares are owned by its staff.

In case of BioXcel Therapeutics stock, 28.52% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BTAI stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to BioXcel:

BTAI
Market cap$925.3 M
Total shares20.2 M
Float shares1.5 M
  - Institutional holdings (%)28.5%
  - Insider holdings (%)48.5%
Shares in short selling0.0%

BioXcel summary

Thursday, May 14th, 2020
Open$42.06
Close$45.85
Day range$41.02 - $46.12
Previous close$43.07
Session gain6.45%
Average true range$4.05
50d mov avg$27.72
100d mov avg$24.22
200d mov avg$15.77
Daily patternlt06a
Weekly pattern lb03c

BioXcel performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For BioXcel, the benchmark is made against .
Stock3m6m12m
BTAIBioXcel Therapeut...24.02%790.29%320.64%

BioXcel competitors

Unfortunately, we could not find any public company that could be defined as BioXcel competitor. This doesn't mean BioXcel does not have any competitor in the market, it's just we could not detected it.